profit from every $100 of sales.
$0$100
Revvity
$154.39-1.67% today
+65.3% in 1 year
1-year low $82.261-year high $165.78
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $71.46 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Revvity sold, what it kept, and what it did with the cash.
Sales went from $3.31 billion in 2022 to $2.86 billion in 2025, with $241 million of profit last year.
SalesProfit
Revvity handed back more cash to shareholders than it generated last year.
Buybacks $821M
Free cash flow 2025$509M
Bought back its own shares$821M
Paid as dividends$33M
Cash vs. debt$920M vs. $3.4B
Revvity vs. similar companies
Revvity grows the slowest of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Revvity | 71.5× · Very expensive | ||
 Illumina | 36.8× · Expensive | ||
 Labcorp Holdings | 34.3× · Expensive | ||
 Quest Diagnostics | 28.8× · Fair price | ||
 Guardant Health | No profit yet |
AI analysis
An AI analyst reads Revvity's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 3,783 | 3,828 | 3,312 | 2,751 | 2,755 | 2,856 | |
| 2,110 | 2,434 | 1,990 | 1,540 | 1,538 | 1,564 | |
| 867 | 1,258 | 743 | 301 | 347 | 357 | |
| 1,051 | 1,570 | 1,183 | 714 | 840 | 766 | |
| 728 | 943 | 569 | 693 | 270 | 241 | |
| 6.49 | 8.08 | 4.58 | 5.55 | 2.20 | 2.07 | |
| 55.8% | 63.6% | 60.1% | 56.0% | 55.8% | 54.8% | |
| 22.9% | 32.9% | 22.4% | 10.9% | 12.6% | 12.5% | |
| 19.2% | 24.6% | 17.2% | 25.2% | 9.8% | 8.4% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 7,960 | 15,001 | 14,130 | 13,565 | 12,392 | 12,168 |
| Cash | 387 | 603 | 454 | 913 | 1,163 | 920 |
| Total debt | 2,179 | 5,131 | 4,595 | 4,065 | 3,326 | 3,398 |
| Total liabilities | 4,225 | 7,859 | 6,747 | 5,692 | 4,726 | 4,918 |
| 3,735 | 7,141 | 7,383 | 7,873 | 7,667 | 7,250 | |
| 112 | 117 | 126 | 125 | 123 | 117 | |
| 11.4% | 8.1% | 5.0% | 1.9% | 3.0% | 2.7% | |
| 19.5% | 13.2% | 7.7% | 8.8% | 3.5% | 3.3% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 892 | 1,411 | 680 | 91 | 628 | 583 | |
| 64 | 86 | 86 | 81 | 87 | 74 | |
| 829 | 1,325 | 594 | 10 | 542 | 509 | |
| Dividends paid | 31 | 32 | 35 | 35 | 34 | 33 |
| 7 | 73 | 81 | 389 | 370 | 821 | |
| 27 | 30 | 52 | 41 | 38 | 23 |
Valuation
- 71.5×
- 28.6×
- –
- 1.5×
- 6.0×
- 33.8×
- 25.7×
- 3.0%
- 1.4%
- 0.3%
Profitability
- 54.8%
- 12.5%
- 8.4%
- 26.7%
- 2.9%
- 3.3%
- 3.3%
- 2.0%
- 3.3%
- 7.6%
Growth
- −5.5%
- −20.4%
- −6.2%
- +0.0%
- −0.6%
Financial health
- 3.2×
- 0.47
- 27.9%
- 3.8×
- 1.72
- 1.41
- 0.24
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 39%of 952
Top 42%of 884
Bottom 15%of 601
Bottom 11%of 886
Top 36%of 987
What analysts expect
- Average price target
- $111.29
- Range
- $95.00 – $125.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | 1.06 | 1.02 | +3.9% |
| Feb 2, 2026 | 1.70 | 1.57 | +8.3% |
| Oct 27, 2025 | 1.18 | 1.14 | +3.5% |
| Jul 28, 2025 | 1.18 | 1.14 | +3.5% |
| Apr 28, 2025 | 1.01 | 0.96 | +5.2% |
| Jan 31, 2025 | 1.42 | 1.37 | +3.6% |
| Nov 4, 2024 | 1.28 | 1.13 | +13.3% |
| Jul 29, 2024 | 1.22 | 1.12 | +8.9% |
0.3%of the share price, paid each year
On $1,000 invested$3a year at today's yield, before tax
+0.0%2020 to 2025
Raised–not every year
Paid per share, each year
$0.28 in 2015 → $0.28 in 2025
How safe it looks
13.6% of its profit
Room to growStretchedMore than it earns: 6.4%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
31No pass
Benjamin Graham
35No pass
Philip Fisher
28No pass
Peter Lynch
21No pass
Joel Greenblatt
2No pass
Charlie Munger
30No pass
Terry Smith
31No pass
Questions about Revvity
Is Revvity a good stock to buy?
A business with weak numbers, priced as if everything goes right. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Revvity AI analysis
What does Revvity do?
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. It is in Medical - Diagnostics & Research, based in Waltham, MA, United States, with 11,000 employees.
Does Revvity pay a dividend?
Yes. At today's price the dividend is 0.3% a year, about 14% of its yearly profit. In 2025 it paid out $32.8 million in dividends.
Is Revvity stock halal?
Yes. Revvity passes our halal screen: its business is permitted and its debt is 20% of its market value, under the 30% limit. How we check
How has Revvity stock done over the past year?
Up 65.3% over the past twelve months, to $154.39. It traded between $82.26 and $165.78 and is 6.9% below its high.
Who are Revvity's competitors?
The largest listed companies in the same industry are Illumina, Labcorp Holdings, Quest Diagnostics and Guardant Health. The peers table on this page compares their profit, growth and price with Revvity's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.